Evidence map›Paper›PMID 30830465›Full record

ArticleMetabolomics : Official journal of the Metabolomic Society2019

Towards quality assurance and quality control in untargeted metabolomics studies.

Richard D Beger, Warwick B Dunn, Abbas Bandukwala, Bianca Bethan, David Broadhurst, Clary B Clish, Surendra Dasari, Leslie Derr, Annie Evans, Steve Fischer and 28 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolomics : Official journal of the Metabolomic Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Reference materials for food authentication.Analytical and bioanalytical chemistry · 2025
    Review
  19. Review
  20. Quality Control and Validation Issues in LC-MS-Based Metabolomics.Methods in molecular biology (Clifton, N.J.) · 2025
    Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Richard D BegerNational Center for Toxicological Research, US Food and Drug Administration, Jefferson, USA. Richard.Beger@fda.hhs.gov.
Warwick B DunnSchool of Biosciences, Phenome Centre Birmingham and Institute for Metabolism and Systems Research, University of Birmingham, Birmingham, B15 2TT, UK. w.dunn@bham.ac.uk.
Abbas BandukwalaFood and Drug Administration, Silver Spring, MD, USA.
Bianca BethanMetanomics Health GmBH, Berlin, Germany.
David BroadhurstEdith Cowan University, Perth, Australia.
Clary B ClishBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Surendra DasariMayo Clinic, Rochester, MN, USA.
Leslie DerrOffice of the Director, National Institutes of Health, Bethesda, MD, USA.
Annie EvansMetabolon, Research Triangle Park, NC, USA.
Steve FischerAgilent Technologies, Santa Clara, CA, USA.
Thomas FlynnFood and Drug Administration, Silver Spring, MD, USA.
Thomas HartungJohns Hopkins School of Public Health, Baltimore, MD, USA.
David HerringtonWake Forest University, Winston-Salem, NC, USA.
Richard HigashiUniversity of Kentucky, Lexington, KY, USA.
Ping-Ching HsuUniversity of Arkansas Medical Sciences, Little Rock, AR, USA.
Christina JonesNational Institute of Standards and Technology, Gaithersburg, MD, USA.
Maureen KachmanUniversity of Michigan, Ann Arbor, MI, USA.
Helen KarusoBiocrates Inc., Innsbruck, Austria.
Gary KruppaBruker Daltronics, Billerica, MA, USA.
Katrice LippaNational Institute of Standards and Technology, Gaithersburg, MD, USA.
Padma MaruvadaNational Institute of Diabetes and Digestive and Kidney Disorders, Bethesda, MD, USA.
Jonathan MosleyNational Exposure Research Laboratory, US Environmental Protection Agency, Athens, GA, USA.
Ioanna NtaiThermo Fisher Scientific, San Jose, CA, USA.
Claire O'DonovanEuropean Molecular Biology Laboratory -European Bioinformatics Institute, Hinxton, UK.
Mary PlaydonNational Cancer Institute, Rockville, MD, USA.
Daniel RafteryUniversity of Washington, Seattle, WA, USA.
Daniel ShaughnessyNational Institute of Environmental Health, Durham, NC, USA.
Amanda SouzaThermo Fisher Scientific, San Jose, CA, USA.
Timothy SpaederMetabolon, Research Triangle Park, NC, USA.
Barbara SpalholzNational Cancer Institute, Rockville, MD, USA.
Fariba TayyariUniversity of Georgia, Athens, GA, USA.
Baljit UbhiAB Sciex, Framingham, MA, USA.
Mukesh VermaNational Cancer Institute, Rockville, MD, USA.
Tilman WalkMetanomics Health GmBH, Berlin, Germany.
Ian WilsonImperial College London, London, UK.
Keren WitkinNational Cancer Institute, Rockville, MD, USA.
Daniel W BeardenNational Institute of Standards and Technology, Charleston, SC, USA.
Krista A ZanettiNational Cancer Institute, Rockville, MD, USA. zanettik@mail.nih.gov.

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
Genomic and Proteomic Architecture of AtherosclerosisR01HL111362 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HERRINGTON, DAVID MCLEOD · 2012 to 2021
$17.2M
Circulating Biomarker Consortium for Pancreatic Cancer Early DetectionU01CA210171 · NCI · DANA-FARBER CANCER INST · PI Michael H. Rosenthal, Brian Matthew Wolpin · 2016 to 2026
$8.7M
Metabolomic Signatures of CAD Associated GenotypesR01HL133932 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BOWDEN, DONALD W, HERRINGTON, DAVID MCLEOD · 2016 to 2019
$2.5M
Intramural EPA EPA999999Intramural NIST DOC 9999-NISTMedical Research Council MR/M009157/1NCI NIH HHS U01 CA210171NHLBI NIH HHS R01 HL111362NHLBI NIH HHS R01 HL133932NIDDK NIH HHS P30 DK017047
6 · The paper itself

Abstract

We describe here the agreed upon first development steps and priority objectives of a community engagement effort to address current challenges in quality assurance (QA) and quality control (QC) in untargeted metabolomic studies. This has included (1) a QA and QC questionnaire responded to by the metabolomics community in 2015 which recommended education of the metabolomics community, development of appropriate standard reference materials and providing incentives for laboratories to apply QA and QC; (2) a 2-day 'Think Tank on Quality Assurance and Quality Control for Untargeted Metabolomic Studies' held at the National Cancer Institute's Shady Grove Campus and (3) establishment of the Metabolomics Quality Assurance and Quality Control Consortium (mQACC) to drive forward developments in a coordinated manner.

Indexed as

HumansLaboratoriesMetabolomicsQuality ControlQuality ImprovementCommunity engagementQuality assurance (QA)Quality control (QC)Reporting metricsTest materials

Identifiers

PMID30830465
PMCPMC6443086

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.